

Genomewide Analyses Define Different Modes of Transcriptional Regulation by Peroxisome Proliferator-Activated Receptor- β/δ (PPAR β/δ)

Till Adhikary¹*, Kerstin Kaddatz¹*, Florian Finkernagel¹*, Anne Schönbauer¹, Wolfgang Meissner¹, Maren Scharfe², Michael Jarek², Helmut Blöcker², Sabine Müller-Brüsselbach¹, Rolf Müller¹*

1 Institute of Molecular Biology and Tumor Research (IMT), Philipps University, Marburg, Germany, **2** Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors with essential functions in lipid, glucose and energy homeostasis, cell differentiation, inflammation and metabolic disorders, and represent important drug targets. PPARs heterodimerize with retinoid X receptors (RXRs) and can form transcriptional activator or repressor complexes at specific DNA elements (PPREs). It is believed that the decision between repression and activation is generally governed by a ligand-mediated switch. We have performed genomewide analyses of agonist-treated and PPAR β/δ -depleted human myofibroblasts to test this hypothesis and to identify global principles of PPAR β/δ -mediated gene regulation. Chromatin immunoprecipitation sequencing (ChIP-Seq) of PPAR β/δ , H3K4me3 and RNA polymerase II enrichment sites combined with transcriptional profiling enabled the definition of 112 *bona fide* PPAR β/δ target genes showing either of three distinct types of transcriptional response: (I) ligand-independent repression by PPAR β/δ ; (II) ligand-induced activation and/or derepression by PPAR β/δ ; and (III) ligand-independent activation by PPAR β/δ . These data identify PPRE-mediated repression as a major mechanism of transcriptional regulation by PPAR β/δ , but, unexpectedly, also show that only a subset of repressed genes are activated by a ligand-mediated switch. Our results also suggest that the type of transcriptional response by a given target gene is connected to the structure of its associated PPRE(s) and the biological function of its encoded protein. These observations have important implications for understanding the regulatory PPAR network and PPAR β/δ ligand-based drugs.

Citation: Adhikary T, Kaddatz K, Finkernagel F, Schönbauer A, Meissner W, et al. (2011) Genomewide Analyses Define Different Modes of Transcriptional Regulation by Peroxisome Proliferator-Activated Receptor- β/δ (PPAR β/δ). PLoS ONE 6(1): e16344. doi:10.1371/journal.pone.0016344

Editor: Laszlo Tora, Institute of Genetics and Molecular and Cellular Biology, France

Received: October 8, 2010; **Accepted:** December 11, 2010; **Published:** January 19, 2011

Copyright: © 2011 Adhikary et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Deutsche Forschungsgemeinschaft (Mu601/12-1 and SFB-TR17/A3) and by the Genomics and Bioinformatics Core Units of the SFB-TR17 and the LOEWE-Schwerpunkt "Tumor and Inflammation." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: rmueller@imt.uni-marburg.de

† These authors contributed equally to this work.

Introduction

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors with essential functions in lipid, glucose and energy metabolism, cell differentiation as well as inflammatory and metabolic disorders [1–4]. The PPAR α , PPAR β/δ and PPAR γ subtypes activate their target genes through binding to specific DNA elements (PPREs) as obligatory heterodimers with the retinoid X receptor (RXR). Their transcriptional activity is modulated by certain lipids, fatty acid derivatives and subtype-selective synthetic ligands that have been developed as potential drugs for the treatment of human metabolic diseases [5]. PPRE-bound PPAR complexes have two distinct functions, i.e., transcriptional repression and transcriptional activation. Agonistic ligands induce a conformational change in PPARs that favors the association with coactivators and the dissociation of corepressors [6]. Several PPAR-associated corepressors have been identified [7–12], but their precise function remains largely obscure. Likewise, it is unclear whether all genes targeted by a given PPAR subtype are regulated in a similar way, or whether distinct

regulatory mechanisms govern the expression of different sets of PPAR target genes.

A genomewide binding site analysis of PPAR γ during adipocyte differentiation by chromatin immunoprecipitation sequencing (ChIP-Seq) revealed an exchange of PPAR β/δ for PPAR γ , presumably switching from repressive to activating complexes on the promoters of key target genes [13]. Bioinformatic analyses of ChIP-chip data also revealed the interaction of C/EBP factors with DNA elements in the vicinity of PPAR γ binding sites in adipocytes [14], while in macrophages an interplay of PPAR γ with both C/EBP and the Ets family member PU.1 was observed [15]. A recent ChIP-chip study of PPAR α binding sites in HepG2 hepatoma cells provides evidence for a crosstalk between PPRE-bound PPAR α and SREBP signaling at some target gene promoters [16]. The same study also points to an interaction between PPAR α and STAT transcription factors in PPAR α -mediated transcriptional repression, consistent with previous observation made with individual target genes. In a different context, PPRE-associated PPAR β/δ has been described to interact with, and mediate the SUMOylation of KLF5, leading

to NCoR/SMRT dissociation, CBP recruitment and consequently transcriptional activation [17].

It has previously been shown that PPARs regulate the differentiation, function and proliferation of myofibroblasts in different model systems [18,19]. These include tumor-bearing *Ppard* null mice, which show a hyperplastic tumor stroma associated with a strongly increased differentiation towards myofibroblasts [20]. A role for PPAR β/δ in myofibroblasts is further suggested by an extensive crosstalk with transforming growth factor- β (TGF β) signaling, which affects the composition of chromatin complexes at common target genes [21,22]. In the present study, we used human myofibroblast-like cells as a model system for a genome-wide analysis of PPAR β/δ -regulated transcription. By combining ChIP-Seq analysis with genome-wide transcriptional profiling we show that, contrary to the prevailing opinion, transcriptional repression and activation are not merely determined by the availability of agonistic ligands, but are governed by gene-specific mechanisms. Based on these data we define different modes of transcriptional regulation by PPRE-bound PPAR β/δ , and correlate these with the structure of PPAR β/δ sites and the biological function of the encoded proteins.

Results and Discussion

Genomewide identification of PPAR β/δ enrichment sites in WPMY-1 cell chromatin

Standard quantitative ChIP-qPCR was initially used to analyze chromatin from WPMY-1 cells for PPAR β/δ occupancy of the well-characterized PPAR-responsive enhancer of the *ANGPTL4* gene, which harbors a cluster of 3 functional PPREs in the third intron at +3.5 kb relative to the transcriptional start site (TSS) [21,23]. We found an ~20-fold enrichment of PPAR β/δ at the PPRE-containing intronic enhancer and a low background signal within 20 kb flanking the TSS (Kaddatz *et al.*, 2010). Deep sequencing of this DNA was then performed using an Illumina genome analyzer II. A total of 20,777,020 reads mappable to unique locations on the human genome were obtained. Analysis of the ChIP-Seq data set using the MACS peak calling algorithm (Zhang *et al.*, 2008) identified a total of 4,542 enrichment peaks (Dataset S1). This is exemplified by the profile for the *ANGPTL4* locus in Figure 1A, and for the *SLC25A20* and *CDKN2* loci in Figures S1 and S2. The *ANGPTL4* ChIP-Seq data are in perfect agreement with the pattern observed by ChIP-qPCR (Kaddatz *et al.*, 2010). Further validation was obtained by ChIP-qPCR for a sample of 40 peaks, which also demonstrated the presence of RXR α at the same genomic loci (Figure 1B and data not shown).

In order to assess the potential biological relevance of the PPAR β/δ enrichment sites, we analyzed the 4,542 enrichment peaks for associations with genomic loci (single nucleotide polymorphisms; SNPs) linked to phenotypes via genome wide association studies (GWAS) (Ramagopalan, 2010). Within this dataset reflecting 47 diseases and other common traits there was a significant enrichment in three groups ($p < 0.05$; Benjamini-Hochberg corrected), i.e., cholesterol, HDL cholesterol and bipolar disorder (Dataset S2). This is in excellent agreement with the known physiological role function of PPAR β/δ in lipid metabolism [1,4] and its reported linkage with bipolar disorder [24].

Most PPAR β/δ enrichment sites were found inside or maximum 25 kb upstream of transcribed genomic regions ($n = 3,544$; 78%; Ensembl 58). These sites were located close to transcriptional start sites (-5000 bp upstream or within the first exon/intron of a TSS ($n = 2,220$; 49% of all peaks), within

intragenic regions ($n = 868$; 19%) or in non-transcribed upstream sequences of the TSS ($n = 456$; 10%). The remaining 22% ($n = 998$) were assigned to more distant regions (>25 kb relative to the nearest TSS).

All peaks with an FDR = 0 were used for a *de novo* motif search (MEME) [25], which yielded a 17-bp consensus sequence (Figure 2C; bottom image and bottom line). This motif is composed of a typical direct repeat 1 (DR1) flanked by a 4-bp extension at the PPAR-binding 5'-half site [26], which is consistent with, and refines, the previously proposed consensus sequence (Figure 2C; upper line) [27]. We then searched all 443 enrichment peaks with an FDR < 0.05 ('high confidence peak set'; Dataset S3; Figures 2A) for a 17-bp consensus sequence using MEME, which yielded a similar motif matching 287 (65%) of the 443 sequences (Figure 2C; top image).

Correlation of PPAR β/δ enrichment sites with promoter regions

The conventional, simple approach of associating peaks with the nearest gene defined in a database often yields uncertain results, because frequently multiple genes are found in the vicinity of an enrichment peak, and transcriptional start sites in databases can be incorrectly assigned. To circumvent this problem we took a different approach. In parallel to PPAR β/δ ChIP-Seq, we performed global analyses of histone H3 lysine-4 trimethylation (H3K4me3) and RNA polymerase II enrichment (Datasets S4 and S5) as markers for active or inducible proximal promoters [28,29]. These ChIP-Seq data were aligned with the data set of high confidence PPAR β/δ enrichment peaks, as shown for the *HSDL2* locus in Figure 1C and two other loci in Figures S1 and S2. This correlation led to the delineation of 414 peaks with H3K4me3 clusters within 200 kb of the PPAR β/δ binding sites (PPAR/H3K4 peak set; Figure 2A), corresponding to 93.5% of all high confidence peaks (Figure 2D). The majority of these genomic regions also showed the presence of RNA polymerase II (70%; Figures 1C, 2D, S1 and S3). Those PPAR β/δ ChIP-Seq peaks that did not co-localize with H3K4me3 clusters may be associated with enhancers [28], located in genes switched off in myofibroblasts, or result from non-functional interaction sites [30].

Identification of PPAR β/δ target genes by combining ChIP-Seq and transcriptional profiling

For genomewide expression profiling of *PPARD*-depleted WPMY-1 cells, we used a pool of validated, *PPAR* subtype-specific siRNAs, which in a previous study was shown to inhibit *PPARD* expression in WPMY-1 myofibroblastic cells by >80% and to interfere with the recruitment of PPAR β/δ to the *ANGPTL4* PPREs *in vivo* [21]. This siRNA pool also inhibited the transcriptional activation of a PPRE-luciferase reporter construct by the PPAR β/δ agonist GW5101516, which was rescued by PPAR β/δ overexpression, arguing against potential off-target effects (Figure S3). Microarray analysis of WPMY-1 cells exposed to control or *PPARD* siRNA and, in parallel, in the presence or absence of GW5101516 (Datasets S6 and S7) enabled the delineation of a subgroup of 118 expression-correlated peaks in the PPAR/H3K4 set, corresponding to 112 genes (Figure 2A, Dataset S8). These genes ("target gene set") showed a ≥ 1.5 -fold change in expression after *PPARD* knockdown or a ≥ 1.2 -fold change after application of GW5101516, and were therefore considered *bona fide* PPAR β/δ target genes (Figure 2E). Surprisingly, only a fraction of genes ($n = 13$; 12%) were both induced by *PPARD* siRNA and activated by GW5101516, suggesting that an agonist-induced switch between repression and activation is not the rule.






Figure 1. Genomewide identification of PPAR β/δ binding sites in WPMY-1 cells by ChIP-Seq. (A) PPAR β/δ enrichment at the genomic *ANGPTL4* locus determined by ChIP-Seq. **(B)** ChIP-qPCR analysis of PPAR β/δ and RXR α binding at 12 genomic loci identified by ChIP-Seq. **(C)** PPAR β/δ , H3K4me3 and RNA polymerase II enrichment peaks detected by ChIP-Seq at the *HSDL2* locus. doi:10.1371/journal.pone.0016344.g001

We next determined the location of PPAR β/δ enrichment sites relative to the linked gene within the target gene set. As expected, there was a slight increase in sites near or within transcribed genes (Figure 2F; 83% TSS-flanking, intragenic or upstream within 25 kb) compared to the unfiltered peak set (Figure 2B; 78%). Panther Biological Pathway term analysis [31] via the DAVID knowledge database [32] showed that the majority of the 10 most enriched terms describing biological processes affected by PPAR β/δ were associated with lipid and carbohydrate metabolism (Figure 2G; Dataset S9). This expected result further supports the target gene set defined in the present study. The same analysis also identified several other groups of target genes that are of potential interest in view of PPAR β/δ 's non-metabolic functions, including hematopoiesis and muscle/heart development.

Different modes of target gene regulation

The response of PPAR β/δ target genes to GW501516 (relative to solvent) and *PPARD* siRNA (relative to control siRNA) was verified by RT-qPCR for a total of 53 genes (Dataset S10), as illustrated by the examples in Figure 3A–C. Based on these data, we defined three different transcriptional responses (Figure 4): upregulation (≥ 1.5 -fold) by *PPARD* siRNA, but no induction (< 1.2 -fold) by ligand (type I; $n = 25$; red data points); upregulation by *PPARD* siRNA and induction by ligand (type II; $n = 14$; blue data points); down-regulation by *PPARD* siRNA, and either no response or weak induction by GW501516 (type III; $n = 14$; green data points). This categorization was also reproducible with a different PPAR β/δ agonist (L165,041), and ligand induction was abolished by *PPARD* siRNA (data not shown).

The data also indicate that the magnitude of induction by ligand approaches the effect of PPAR β/δ depletion for individual genes showing a type II response (Figures 3A–C, 4). Since the concentration of GW501516 used (0.3 μ M) causes the maximally achievable transcriptional induction (our unpublished observation), this suggests that ligand-induced transcription results to a large extent from the release of a PPAR β/δ -RXR repressor complex. This postulated PPAR subtype-specific repressive function is consistent with the observation that the siRNA-mediated depletion of PPAR α or PPAR γ did not have any detectable effect on *ANGPTL4* expression (Figure 3D). Furthermore, a triple knockdown of all three PPAR subtypes had a similar effect as the selective PPAR β/δ knockdown (Fig. 3D), suggesting that PPAR α and PPAR γ do not activate target genes that are normally repressed by PPAR β/δ . This finding is important in view of the fact that PPAR β/δ depletion leads to a compensatory upregulation of PPAR α and PPAR γ (Figure S4).

To obtain further evidence for a direct role of PPAR β/δ in both ligand-induced and ligand-independent responses, we analyzed the effect of *PPARD* siRNA on the chromatin association of PPAR β/δ at representative target genes, i.e., *IMPA2* and *MLYCD* (type I) and *ANGPTL4* and *SLC25A20* (type II). The data in Fig. 3E shows that in each case siRNA treatment led to clear loss of PPAR β/δ irrespective of the different transcriptional outcomes (Fig. 3A, B). These results support the conclusion that ligand-independent responses are directly linked to the recruitment of PPAR β/δ to the respective target genes.

The ligand-independent activation of type III response genes by PPAR β/δ may suggest a role for endogenous ligands produced by WPMY-1 cells. This is, however, unlikely in view of the fact that

type II response genes are activated by GW501516 under the identical experimental conditions (Fig. 3B, C). Furthermore, a typical type III response was also seen in HepG2 hepatoma cells with several tested genes, including *BIRC3* and *AHNAK* (our unpublished observation). Finally, a clear transcriptional induction of *ANGPTL4* was also seen with agonists that have a substantially lower affinity than the synthetic GW501516, such as 15-HETE [33], arguing against the possibility that WPMY-1 cells produce particularly high levels of endogenous PPAR β/δ ligands.

Structural features associated different types of response

This validated gene set was used for the identification of potential response-selective DNA sequence motifs within the associated ChIP-Seq peaks. *De novo* motif search in peak areas associated with both type I and type II responses identified motifs (Figure 5A) that closely resembled the consensus DR1 sequence defined above (see Figure 2C). However, only the type II-associated motif perfectly matched both the DR-1 motif and the 5' extension. In contrast, no correlations were found between the type of response of a given gene, the position of PPAR β/δ enrichment peak(s) and the number of PPREs (Figure 5B). It is therefore tempting to speculate that the structurally different PPREs may contribute to the distinct type I and II responses, for instance by inducing binding site specific conformations of the interacting protein complexes, as reported for the thyroid hormone receptor [34]. This is conceivable, since the 5' extension characteristic of type II-associated PPREs has been shown to contribute to PPAR γ -RXR binding by contacting a region adjacent to the zinc finger of the PPAR protein [26].

In contrast to genes showing type I or II responses, a clear consensus motif search in type III-associated peaks did not yield a defined consensus motif, but frequently imperfect PPREs or extended PPRE half-sites could be identified (Figure 5A; Dataset S10), suggesting that the role of PPAR β/δ may be to assist other factor(s) in transcriptional activation. However, at present we do not know whether these PPRE-like sequences are functionally relevant. It is, therefore, also possible that PPAR β/δ enrichment at some of the type III response genes is due to PPRE-unrelated mechanisms, resulting for instance from an interaction of PPAR β/δ with other DNA-binding transcription factors.

Cell type-specific determinants

Several lines of evidence suggest that the regulation of PPAR β/δ target genes is not only determined by the genomic context, as shown in the present study, but also by cell type specific determinants. First, a comparison with published data shows that some genes characterized by a ligand-independent type I or type III response in WPMY-1 cells (Fig. 3A; Dataset S7) are inducible by PPAR β/δ agonists in other cell types, for example *IMPA2* in diploid human fibroblasts [22] or *HMOX1* in endothelial cells [35]. Second, the *PDPK1* and *ILK* genes, which are ligand-inducible in mouse keratinocytes [36], are unresponsive to ligand in WPMY-1 cells (Dataset S7). Although both genes respond to *PPARD* siRNA (Dataset S7), our ChIP-Seq analysis did not show an enrichment of PPAR β/δ binding at these loci (Dataset S1), suggesting that the siRNA effect in WPMY-1 cells is due to secondary events. Third, the *ANGPTL4* gene is strongly induced by PPAR β/δ in WPMY-1 cells (Fig. 3A) and other cell types [21–23,33,37,38], but shows a type I response in HepG2 cells, even though other PPAR β/δ target




Figure 2. Genomewide identification of PPAR β/δ target genes by combining ChIP-Seq and transcriptional profiling. (A) Flow chart showing consecutive steps of bioinformatic analysis for the definition of high confidence PPAR β/δ -regulated genes (target gene set). These genes are characterized by one or more peaks with an FDR<0.05 that is/are located within 200 kb of a database-defined gene (Ensembl release 58), a cluster of H3K4me3 marks, RNA polymerase II enrichment and transcriptional responsiveness to *PPARD* siRNA and/or the agonist GW501516. (B) Distribution of genomewide PPAR β/δ binding for all 4,542 peaks identified by ChIP-Seq. *TSS flanking* is defined as regions from -5000 bp to the 3' end of the first intron, *upstream* regions are located within -25 kb of a transcriptional start site (TSS). (C) Consensus sequence identified by *de novo* motif search (MEME) [25] of ChIP-Seq in high confidence (top) and FDR=0 peaks (bottom). The line beneath shows the published consensus sequence [27]; the bottom line (boldface) shows the refined sequence derived from the present study. (D) Overlap between high confidence PPAR β/δ peaks, H3K4me3 marks and RNA polymerase II enrichment detected by parallel ChIP-Seq experiments. (E) Venn diagram showing the overlap between genes regulated by *PPARD* siRNA or activated by GW501516. (F) Analysis of PPAR β/δ peak distribution for the target gene set. (G) Panther biological process (BP) classification of the target gene set. The 10 most enriched BP terms describing biological processes affected by PPAR β/δ are shown. doi:10.1371/journal.pone.0016344.g002




Figure 3. Identification of different types of transcriptional responses to PPAR β/δ depletion and ligands. (A–C) Differential responses to GW501516 and *PPARD* siRNA of PPAR β/δ target genes, classified as type I (A), type II (B) and type III (C) responses. WPMY-1 cells were treated as indicated and analyzed as in Figure 1. Data from four biological replicates are shown. Individual data points represent the average of 3 technical replicates. Horizontal lines indicate the median of 4 biological replicates. (D) PPAR subtype-specific repression of the *ANGPTL4* gene by PPAR β/δ . WPMY-1 cells were transfected with *PPARA*, *PPARG* or *PPARD* siRNA pools, or a combination of all three pools (triple knock-down), and relative *ANGPTL4* mRNA levels were measured by RT-qPCR. The efficiencies and subtype specificities of the siRNA pools are shown in Figure S4. (E) Effect of *PPARD* siRNA treatment on PPAR β/δ recruitment to the *IMPA2*, *MLYCD*, *ANGPTL4*, *SLC25A20*, *BIRC3* and *GPR180* genes.
doi:10.1371/journal.pone.0016344.g003

genes (like *ADRP* or *CPT1A*) show a similar response in HepG2 and WPMY-1 cells (our unpublished observation). Taken together, these findings suggest that the cell type dependent availability or expression level of factors functionally and/or physically interacting with PPAR β/δ is an important co-determinant of the type of response of PPAR β/δ target genes.

Correlation of the type of response with the biological function of target genes

Intriguingly, most validated genes showing a type II response (10/15; 67%) are directly associated with lipid metabolism, which is clearly different from the type I and III groups (5/24 and 0/0, respectively, corresponding to 21% and 0%). Likewise, Panther BP term classification identified a single significant hit across all three groups of genes, i.e. “lipid, fatty acid and steroid metabolism” for the type II response group with a *P* value of 0.0002 (Benjamini-Hochberg corrected) compared to *P*=0.29 for type I response genes. These observations clearly point to a link between the

biological function of PPAR β/δ target genes and their integration into a regulatory network.

Conclusions

Our genomewide binding and expression studies with human myofibroblasts strongly suggest that PPRE-directed regulation by PPAR β/δ is not governed by a single mechanism. While repression in the absence of an agonistic ligand is commonly observed (with both type I and II responses), only the type II response involves an upregulation by ligand, which appears to be mediated to a major extent by release from transcriptional repression. Inspection of PPREs mediating type I and II responses suggests that their structure correlates with the differential response of the associated genes to ligands. On the other hand, genes showing a type III response are activated by PPAR β/δ in the absence of exogenous ligand, pointing to fundamentally different regulatory PPAR β/δ complexes. This scenario is reminiscent of the *Fabp4* gene in murine adipocytes which is




Figure 4. Correlation of *PPARD* siRNA and GW501516 mediated gene regulation for the validated gene set. Red: type I response, upregulated (≥ 1.5 -fold) by *PPARD* siRNA and unaffected by GW501516; blue: type II response, upregulated by *PPARD* siRNA and induced by GW501516 (≥ 1.2 -fold); green: type III response, down-regulated (≥ 1.5 -fold) by *PPARD* siRNA. Each data point represents the average of 4 biological replicates as in Figure 3A–C.
doi:10.1371/journal.pone.0016344.g004




Figure 5. Structural features of PPAR β/δ target genes showing type I or type II responses. (A) Consensus PPRE motifs in ChIP-Seq peak areas of validated type I, II and III response genes derived by best-fit alignment of peak sequences with the FDR=0 motif in Fig. 2C. (B) Locations of PPREs in PPAR β/δ enrichment peaks (type I: red; type II: blue; numbers relative to the TSS). All sites downstream of the TSS are intragenic.
doi:10.1371/journal.pone.0016344.g005

constitutively activated by PPAR γ in the absence of ligand, while under the same conditions the *Gy/k* gene is ligand-dependent [9]. However, similar gene-specific responses have not been described for PPAR β/δ to date, although an agonist-independent association of PPAR β/δ with coactivators is structurally conceivable [39].

The existence of different modes of regulation suggests that PPAR β/δ is able to exert different biological functions, which is determined by the presence of ligands, its own expression level and the availability with specific coregulators. This hypothesis is

supported by the results of our biological term classification, which showed that ligands affect primarily genes involved in lipid metabolism, suggesting that the biological function of PPAR β/δ target genes is indeed linked to the mode of their regulation. Taken together, these observations have important implications for elucidating the global PPAR β/δ signaling network and for understanding the function of ligand-based drugs in physiological and disease-related processes.

Materials and Methods

Cell culture and ligands

WPMY-1 cells [40] were obtained from the ATCC and maintained as described [21]. GW501516 and was from Axxora (Lörrach, Germany) and L165,041 from Calbiochem (Merck, Darmstadt, Germany).

siRNA transfections

Cells were seeded at a density of 5×10^5 cells per 6 cm dish in 4 ml DMEM with 10% FCS and cultured for 2 h. 1280 ng siRNA in 100 μ l OptiMEM (Invitrogen) and 20 μ l HiPerfect (Qiagen, Hilden, Germany) were mixed and incubated for 5–10 min at room temperature prior to transfection. The cells were replated 24 h post-transfection at a density of 5×10^5 cells per 6 cm dish. Transfection was repeated 48 h after start of the experiment, and cells were passaged after another 24 h. Forty-eight hours following the last transfection, cells were stimulated and harvested after another 6 h.

Quantitative RT-PCR

cDNA was synthesized from 0.1–1 μ g of RNA using oligo(dT) primers and the Omniscript kit (Qiagen, Hilden, Germany). qPCR was performed in a Mx3000P Real-Time PCR system (Stratagene, La Jolla, CA) for 40 cycles at an annealing temperature of 60°C. PCR reactions were carried out using the Absolute QPCR SYBR Green Mix (Abgene, Hamburg, Germany) and a primer concentration of 0.2 μ M following the manufacturer's instructions. *L27* was used as normalizer. Comparative expression analyses were statistically analyzed by Student's *t*-test (two-tailed, equal variance) and corrected for multiple hypothesis testing via the Bonferroni method. RT-qPCR primer sequences are included in Dataset S10.

Microarrays

Microarray analyses were carried out as published [21]. Raw microarray data were normalized using the 'loess' method implemented within the marray package of R/Bioconductor [41]. Raw and normalized microarray data were deposited at EBI ArrayExpress (E-MEXP-2756). All data is MIAME compliant. Probes were considered regulated if they had an averaged log intensity ≥ 6 and a fold change ≥ 1.2 for GW501516 and ≥ 1.5 and siPPARD, respectively. Agilent microarray probes were aligned to both the reference genome (GRch37) and virtual cDNA created from Ensembl release 58 [42] and assigned to members of the Ensembl release 58 Homo sapiens gene set (see below). Genes with multiple probes passing the intensity threshold were assigned to the most strongly regulated probe for peak association.

Assignment of microarray probes to genes

Agilent microarray probes were aligned to both the reference genome (GRch37) and in silico cDNA created from Ensembl release 58 (Hubbard et al. 2009) using bowtie 0.12.3, allowing 3 mismatches in the seed and 5 mismatches in total (Dataset S11).

They were assigned to (possibly multiple) genes in the following order:

- perfect match in transcripts of a single gene,
- perfect match in transcripts of multiple genes, only one with matches within 2 kb of its transcripts 3'-ends,
- perfect genomic matches in different genes (no genes assigned),
- perfect genomic match to only one gene,
- perfect genomic match in one location covered by multiple genes,
- perfect genomic match outside of a gene with multiple matches to transcripts of different genes,
- perfect genomic match to a gene within 2 kb,
- perfect genomic match outside of a gene region (no gene assigned),
- mismatch in transcripts of a single gene,
- mismatch in transcripts of multiple genes, only one with matches within 2 kb of its transcripts 3'-ends,
- genomic mismatches in different genes (no genes assigned),
- mismatch to only one gene,
- mismatch in one location covered by multiple genes,
- mismatch outside of a gene with multiple matches to transcripts of different genes,
- mismatch to a gene within 2 kb,
- mismatch outside of a gene region (no gene assigned).

ChIP-qPCR and ChIP Sequencing (ChIP-Seq)

ChIP-qPCR was performed and evaluated as described [21] using the following antibodies: IgG pool, I5006 (Sigma-Aldrich, Steinheim, Germany); α -PPAR β/δ , sc-7197; α -RXR α , sc-774; α -RNA polymerase II, sc-599; (Santa Cruz, Heidelberg, Germany); α -H3K4me3, pAb-003-050 (Diagenode, Liège, Belgium). Primer sequences are listed in Table S1. For ChIP-Seq, ChIP samples from WPMY-1 cells were sequenced on an Illumina Ix Genome Analyzer and analyzed with Bowtie [43] and MACS [44]. Sequencing data were deposited at EBI ArrayExpress (E-MTAB-371).

Mapping of ChIP-Seq reads

Sequence reads (36 bp) were approximately deduplicated using a bloom filter (collision probability 10^{-8}) and aligned to the human genome (GRCh37) with bowtie 0.12.3 [43] allowing at most two mismatches ($-n\ 2$) with a mismatch quality sum of 70 ($-e\ 70$) and restricting to exactly one mapped location ($-m\ 1\ -k\ 1$). Out of 33,078,626 PPAR β/δ total reads in three lanes, 20,777,020 unique reads could be aligned to distinct locations of the human genome ('were mappable'); 1,553,813 failed to align. Out of 16,945,431 H3K4me3 reads in one lane, 10,183,043 were mappable and 935,169 failed to align. For RNA polymerase II (one lane) the numbers were 19,967,069, 10,248,554 and 2,178,974, respectively, and the three control IgG lanes yielded 62,436,651 total, 42,197,561 mappable and 3,394,035 failed reads.

Peak finding

The aligned reads of multiple sequencing runs were combined as appropriate and passed to MACS [44] ($--tsize=36$, $--gsize=2900000000$ $--mfold=8$) for peak finding, with the same IgG background used in both comparisons, PPAR β/δ and H3K4me3 (see Datasets S1 and S4 for results). To generate a high confidence PPAR β/δ peak set of 443 elements (Dataset S3), only peaks with a MACS-assigned FDR of less than 5% and fewer than 100 tags in the

IgG track were selected. Furthermore, 17 peaks were removed from this set manually after visual inspection because of low signal-to-noise ratios. PPAR β/δ peaks without a H3K4me3 peak within 200 kbp were filtered, leading to the peak set titled "PPAR/H3K4". RNA polymerase II occupancy was assessed for those H3K4me3 peaks having more than 50 Pol II tags in their region. Finally, we assigned the remaining 414 peaks to nearby regulated genes (see below: assignment of microarray probes), yielding a target gene set of 118 peaks corresponding to 112 genes (Dataset S8).

Databases

The reference genome used throughout was the human genome assembly GRCh37 (<http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/index.shtml>). All gene and transcript data, such as transcription start site positions, came from Ensembl revision 58 (<http://may2010.archive.ensembl.org/>). Functional annotation was retrieved from DAVID [32], genome wide association data from the supplemental data of [40].

Comparison with single nucleotide polymorphism (SNP) data

Single nucleotide polymorphisms associated with phenotypes by genome wide association studies (GWAS) from reference [45] were extended by 200 kb on each side, and the percentage base pair overlap with the intervals of a query set (peaks) was measured. To evaluate the resulting scores, a Monte Carlo simulation with approximately $n=10,000$ trials was performed. Non-occurrence within the trials was assigned a p-value of $3/N$, and the result was corrected by the Benjamini-Hochberg procedure. The null model in the simulation retained the number of intervals, their sizes and their distance to the closest transcription start site in order to simulate random transcription factor binding sites. Enrichment was defined as the observed overlap divided by the mean overlap within the Monte Carlo simulation.

Functional assignments

Gene sets were intersected with biological pathways as defined by Panther [31] (www.pantherdb.org) via the DAVID knowledge database [32] (<http://david.abcc.ncifcrf.gov>; release 6.7), using Ensembl gene ids as the main identifier. P-value was assessed by a corrected hyper geometric test (DAVID's EASE score) and correction for multiple hypothesis testing was done via the Benjamini-Hochberg procedure.

Motif search

De novo motif search was performed using MEME (version 4.3.0) [25]. MEME parameters were " $-dna\ -mod\ zoops\ -minw\ 10\ -maxw25\ -maxsize\ 100000\ -revcomp\ -p\ 7$ " for Fig. 2C (FDR = 0 motif) and " $-dna\ -mod\ zoops\ -minw\ 17\ -maxw17\ -maxsize\ 100000\ -revcomp\ -p\ 7$ " for subsequent motif searches.

Supporting Information

Figure S1 Detection of PPAR β/δ , H3K4me3 and RNA polymerase II enrichment peaks at the *SLC25A20* locus by ChIP-Seq.

(TIFF)

Figure S2 Detection of PPAR β/δ , H3K4me3 and RNA polymerase II enrichment peaks at the *CDKN2C* locus by ChIP-Seq.

(TIFF)

Figure S3 *PPARD* siRNA-mediated inhibition of ligand-induced transcriptional activation of PPAR β/δ . WPMY-1

cells were transfected with a PPRE-luciferase construct in the presence of control or *PPARD* siRNA and treated with GW501516 for 24 hrs. The knockdown effect was abolished by cotransfection of a *PPARD* expression vector.
(TIFF)

Figure S4 Efficiency and specificity of the siRNA-mediated knockdown of *PPARA*, *PPARG* and *PPARD*. WPMY1-1 cells were transfected with the indicated siRNA pools or control siRNA (si-con) and relative expression levels of *PPARA*, *PPARG* and *PPARD* were measured by RT-qPCR.
(TIFF)

Table S1 Primers used for RT-qPCR analyses.
(PDF)

Dataset S1 ChIP-Seq data set of all PPAR β/δ enrichment peaks (complete list; $n = 4,542$).
(XLS)

Dataset S2 Comparison of PPAR β/δ enrichment peaks with SNP data.
(XLS)

Dataset S3 High confidence PPAR β/δ peak set ($n = 443$), consisting of peaks with a MACS-assigned FDR of less than 5% and fewer than 100 tags in the IgG track.
(XLS)

Dataset S4 ChIP-Seq data set of histone H3 lysine-4 trimethylation (H3K4me3) enrichment peaks (complete list; $n = 24,843$).
(XLS)

Dataset S5 ChIP-Seq data set of RNA polymerase II enrichment in genes (complete list).
(XLS)

References

- Desvergne B, Michalik L, Wahli W (2006) Transcriptional regulation of metabolism. *Physiol Rev* 86: 465–514.
- Kilgore KS, Billin AN (2008) PPARbeta/delta ligands as modulators of the inflammatory response. *Curr Opin Investig Drugs* 9: 463–469.
- Peters JM, Gonzalez FJ (2009) Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. *Biochim Biophys Acta* 1796: 230–241.
- Grimaldi PA (2010) Metabolic and nonmetabolic regulatory functions of peroxisome proliferator-activated receptor beta. *Curr Opin Lipidol* 21: 186–191.
- Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM (2006) The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). *Toxicol Sci* 90: 269–295.
- Yu S, Reddy JK (2007) Transcription coactivators for peroxisome proliferator-activated receptors. *Biochim Biophys Acta* 1771: 936–951.
- Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunnyak V, et al. (2000) Combinatorial roles of the nuclear receptor corepressor in transcription and development. *Cell* 102: 753–763.
- Shi Y, Hon M, Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. *Proc Natl Acad Sci U S A* 99: 2613–2618.
- Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA (2005) Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. *Genes Dev* 19: 453–461.
- Sample RK, Meirhaeghe A, Vidal-Puig AJ, Schwabe JW, Wiggins D, et al. (2005) A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. *Endocrinology* 146: 1871–1882.
- Ricote M, Glass CK (2007) PPARs and molecular mechanisms of transrepression. *Biochim Biophys Acta* 1771: 926–935.
- Nofsinger RR, Li P, Hong SH, Jonker JW, Barish GD, et al. (2008) SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. *Proc Natl Acad Sci U S A* 105: 20021–20026.
- Nielsen R, Pedersen TA, Hagenbeck D, Moulos P, Siersbaek R, et al. (2008) Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. *Genes Dev* 22: 2953–2967.
- Lefterova MI, Zhang Y, Steger DJ, Schupp M, Schug J, et al. (2008) PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. *Genes Dev* 22: 2941–2952.
- Lefterova MI, Steger DJ, Zhuo D, Qatanani M, Mullican SE, et al. (2010) Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. *Mol Cell Biol* 30: 2078–2089.
- van der Meer DL, Degenhardt T, Vaisanen S, de Groot PJ, Heinaniemi M, et al. (2010) Profiling of promoter occupancy by PPAR{alpha} in human hepatoma cells via ChIP-chip analysis. *Nucleic Acids Res*.
- Oishi Y, Manabe I, Tobe K, Ohsugi M, Kubota T, et al. (2008) SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. *Nat Med*.
- Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, et al. (2007) The Role of PPARs in Lung Fibrosis. *PPAR Res* 2007: 71323.
- Müller R, Kömhoff M, Peters JM, Müller-Brüsselbach S (2008) A Role for PPAR β/δ in Tumor Stroma and Tumorigenesis. *PPAR Res* 2008: 534294.
- Müller-Brüsselbach S, Kömhoff M, Rieck M, Meissner W, Kaddatz K, et al. (2007) Deregulation of tumor angiogenesis and blockade of tumor growth in PPAR β -deficient mice. *Embo J* 26: 3686–3698.
- Kaddatz K, Adhikary T, Finkernagel F, Meissner W, Müller-Brüsselbach S, et al. (2010) Transcriptional profiling identifies functional interactions of TGF β and PPAR β/δ signaling: synergistic induction of ANGPTL4 transcription. *J Biol Chem* 285: 29469–29479.
- Stockert J, Adhikary T, Kaddatz K, Finkernagel F, Meissner W, et al. (2010) Reverse crosstalk of TGF β and PPAR β/δ signaling identified by transcriptional profiling. *Nucleic Acids Res*;doi:10.1093/nar/gkq773.
- Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, et al. (2004) The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. *J Biol Chem* 279: 34411–34420.
- Zandi PP, Belmonte PL, Willour VL, Goes FS, Badner JA, et al. (2008) Association study of Wnt signaling pathway genes in bipolar disorder. *Arch Gen Psychiatry* 65: 785–793.
- Bailey TL, Elkan C (1994) Fitting a mixture model by expectation maximization to discover motifs in biopolymers. *Proc Int Conf Intell Syst Mol Biol* 2: 28–36.

Dataset S6 Microarray analysis of WPMY-1 cells treated with *PPARD* or control or siRNA (complete list).
(XLS)

Dataset S7 Microarray analysis of WPMY-1 cells exposed to GW501516 or solvent (complete list).
(XLS)

Dataset S8 “Target gene set” defined by correlating ChIP-Seq and microarray data ($n = 112$).
(XLS)

Dataset S9 Panther Biological Pathway term analysis of the target gene set.
(XLS)

Dataset S10 Data set of validated target genes ($n = 53$), including primers used for RT-qPCR analyses.
(XLS)

Dataset S11 Alignment of Agilent microarray probes to both the reference genome (GRch37) and in silico cDNA created from Ensembl release 58.
(XLS)

Acknowledgments

We are grateful to Dr. M. Krause and Olesja Popow for help with microarrays and RT-qPCRs, respectively.

Author Contributions

Conceived and designed the experiments: TA KK FF SMB RM. Performed the experiments: TA KK AS WM MS. Analyzed the data: TA KK FF MJ HB SMB RM. Wrote the paper: RM.

26. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, et al. (2008) Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. *Nature*. pp 350–356.
27. Ijpenberg A, Jeannin E, Wahli W, Desvergne B (1997) Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. *J Biol Chem* 272: 20108–20117.
28. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* 447: 799–816.
29. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, et al. (2007) Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. *Nat Genet* 39: 311–318.
30. Biddie SC, John S, Hager GL (2010) Genome-wide mechanisms of nuclear receptor action. *Trends Endocrinol Metab* 21: 3–9.
31. Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, et al. (2010) PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. *Nucleic Acids Res* 38: D204–210.
32. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4: 44–57.
33. Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, et al. (2010) 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor β/δ agonist. *Mol Pharmacol* 77: 171–184.
34. Berghagen H, Ragnhildstveit E, Krogsrud K, Thuestad G, Apriletti J, et al. (2002) Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3Ralpha from a negative hormone response element. *J Biol Chem* 277: 49517–49522.
35. Ali F, Ali NS, Bauer A, Boyle JJ, Hamdulay SS, et al. (2010) PPARdelta and PGC1alpha act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to stress. *Cardiovasc Res* 85: 701–710.
36. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. *Mol Cell* 10: 721–733.
37. Girroir EE, Hollingshead HE, Billin AN, Willson TM, Robertson GP, et al. (2008) Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. *Toxicology* 243: 236–243.
38. He P, Borland MG, Zhu B, Sharma AK, Amin S, et al. (2008) Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell lines. *Toxicology* 254: 112–117.
39. Molnar F, Matilainen M, Carlberg C (2005) Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. *J Biol Chem* 280: 26543–26556.
40. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, et al. (1999) A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. *Carcinogenesis* 20: 1185–1192.
41. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 5: R80.
42. Hubbard TJ, Aken BL, Ayling S, Ballester B, Beal K, et al. (2009) Ensembl 2009. *Nucleic Acids Res* 37: D690–697.
43. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10: R25.
44. Zhang Y, Liu T, Meyer CA, Eeckhoutte J, Johnson DS, et al. (2008) Model-based analysis of ChIP-Seq (MACS). *Genome Biol* 9: R137.
45. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, et al. (2010) A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. *Genome Res* 20: 1352–1360.